Why the study?
Medications for atrial fibrillation may have significant drug interactions with emerging COVID-19 treatments, leading to adverse clinical consequences.
Provides practical guidance on managing atrial fibrillation in COVID-19 patients, emphasizing the critical need to monitor for drug-drug interactions.
No takes yet. Share an insight, caveat, or question.
Clinicians should screen for interactions between AF therapies and COVID-19 treatments; leaves open effects on clinical outcomes.
Rattanawong et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: